MYAM
SRPT icon

Meiji Yasuda Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Meiji Yasuda Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,347
Closed -$285K – 685
2024
Q4 		$285K Hold
2,347
– – 0.01% 561
2024
Q3 		$293K Sell
2,347
-49
-2% -$6.77K 0.01% 556
2024
Q2 		$379K Buy
+2,396
New +$308K 0.02% 479

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Meiji Yasuda Asset Management's SRPT Position: Q1 2025 in Review

Meiji Yasuda Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,347 shares — an estimated $285K sold.

Meiji Yasuda Asset Management first reported a position in SRPT in Q2 2024 and held it in 3 quarters. The position peaked at $379K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Meiji Yasuda Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Meiji Yasuda Asset Management sold 2,347 Sarepta Therapeutics shares in Q1 2025, an estimated $285K.
  • Meiji Yasuda Asset Management first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 3 quarters.
  • Meiji Yasuda Asset Management's Sarepta Therapeutics position peaked at $379K in Q2 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Meiji Yasuda Asset Management's 13F filing for Q1 2025, filed 16 May 2025.